{
  "id": "5c72bfcd7c78d6947100007a",
  "type": "summary",
  "question": "What is CVT-301?",
  "ideal_answer": "CVT-301 is inhaled levodopa (LD) formulation for development as a self-administered treatment for relief of OFF periods in Parkinson's disease.  CVT-301 provided rapid improvement of motor function, and daily OFF time was significantly reduced at the higher dose.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27733560",
    "http://www.ncbi.nlm.nih.gov/pubmed/27090868",
    "http://www.ncbi.nlm.nih.gov/pubmed/28494719",
    "http://www.ncbi.nlm.nih.gov/pubmed/29161531",
    "http://www.ncbi.nlm.nih.gov/pubmed/27743318",
    "http://www.ncbi.nlm.nih.gov/pubmed/27345931",
    "http://www.ncbi.nlm.nih.gov/pubmed/30479171"
  ],
  "snippets": [
    {
      "text": "Further approaches to enhance LD efficacy are focused on new non-oral administration routes, including nasal, intra-duodenal, intrapulmonary (CVT-301) and subcutaneous (ND0612), as well as on novel ER formulations, including IPX066, which recently concluded phase III trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28494719",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29161531",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: CVT-301, an inhaled levodopa (LD) formulation, is under development for relief of OFF periods in Parkinson's disease (PD). Previously, we reported that CVT-301 improved OFF symptoms relative to placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29161531",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30479171",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Areas covered: CVT-301 is a self-administered dry powder aerosol inhaled formulation of LD that is being developed as a self-administered treatment for OFF periods.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30479171",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "During a placebo-controlled trial of an inhaled levodopa formulation, CVT-301, in PD patients with \u22652 h/d of OFF time, spirometry was performed by American Thoracic Society (ATS) guidelines at screening and throughout the 4-week treatment period.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345931",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ND0612 is a proprietary liquid formulation of LD/CD that enables subcutaneous administration via a small patch-pump device, and CVT-301 is a levodopa inhalation powder with rapid onset of action; both are currently in active studies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27743318",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CVT-301 is a powder formulation of levodopa delivered by a breath-actuated inhaler that has been developed for treating OFF episodes (motor fluctuations between doses of standard oral levodopa) in patients with Parkinson's disease (PD). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27733560",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CVT-301 is a levodopa inhalation powder with the potential for rapid onset of action. The objective of this study was to evaluate CVT-301 self-administered by PD patients to relieve OFF episodes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27090868",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: CVT-301 self-administered during OFF episodes provided rapid improvement of motor function, and daily OFF time was significantly reduced at the higher dose. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27090868",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nCVT-301, an inhaled levodopa (LD) formulation, is under development for relief of OFF periods in Parkinson's disease (PD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29161531",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CVT-301 is a levodopa inhalation powder with the potential for rapid onset of action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27090868",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27090868",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CVT-301 is a powder formulation of levodopa delivered by a breath-actuated inhaler that has been developed for treating OFF episodes (motor fluctuations between doses of standard oral levodopa) in patients with Parkinson's disease (PD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27733560",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: CVT-301 is a self-administered dry powder aerosol inhaled formulation of LD that is being developed as a self-administered treatment for OFF periods.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30479171",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CVT-301 is a levodopa inhalation powder with the potential for rapid onset of action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27090868",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}